1. Home
  2. ELVN vs EFC Comparison

ELVN vs EFC Comparison

Compare ELVN & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • EFC
  • Stock Information
  • Founded
  • ELVN 2016
  • EFC 2007
  • Country
  • ELVN United States
  • EFC United States
  • Employees
  • ELVN N/A
  • EFC N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • EFC Real Estate
  • Sector
  • ELVN Health Care
  • EFC Finance
  • Exchange
  • ELVN Nasdaq
  • EFC Nasdaq
  • Market Cap
  • ELVN 1.0B
  • EFC 1.1B
  • IPO Year
  • ELVN 2020
  • EFC 2010
  • Fundamental
  • Price
  • ELVN $22.35
  • EFC $12.62
  • Analyst Decision
  • ELVN Strong Buy
  • EFC Buy
  • Analyst Count
  • ELVN 5
  • EFC 5
  • Target Price
  • ELVN $37.80
  • EFC $13.69
  • AVG Volume (30 Days)
  • ELVN 269.1K
  • EFC 886.4K
  • Earning Date
  • ELVN 03-13-2025
  • EFC 02-24-2025
  • Dividend Yield
  • ELVN N/A
  • EFC 12.54%
  • EPS Growth
  • ELVN N/A
  • EFC 21.68
  • EPS
  • ELVN N/A
  • EFC 1.32
  • Revenue
  • ELVN N/A
  • EFC $290,293,000.00
  • Revenue This Year
  • ELVN N/A
  • EFC N/A
  • Revenue Next Year
  • ELVN N/A
  • EFC $26.40
  • P/E Ratio
  • ELVN N/A
  • EFC $9.59
  • Revenue Growth
  • ELVN N/A
  • EFC 12.72
  • 52 Week Low
  • ELVN $10.90
  • EFC $10.88
  • 52 Week High
  • ELVN $30.03
  • EFC $13.46
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 47.03
  • EFC 58.48
  • Support Level
  • ELVN $20.40
  • EFC $12.26
  • Resistance Level
  • ELVN $22.42
  • EFC $12.72
  • Average True Range (ATR)
  • ELVN 1.25
  • EFC 0.16
  • MACD
  • ELVN 0.06
  • EFC 0.01
  • Stochastic Oscillator
  • ELVN 59.59
  • EFC 78.26

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

Share on Social Networks: